Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (266)	2/11/1999 12:20:00 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 804

DAK: From ENMD 1997 10K: <<Bristol-Myers Squibb also received a five year right of first refusal with respect to the development of any technology licensed or to be licensed by the Company from Children's Hospital in the field of antiangiogenic therapeutics.>> In Dec. 1995, when ENMD and BMY sign agreement, edostatin and other angiogenic proteins were in ear. Not to limit any company freedom and Children's option, they were not able to sign option (which means fee for option and fixed price) for future real possibility. Instead they signed right to first refusal as guaranty for BMY to (without going in to biding war with other pharmas)license other proteins at the fair price for both company. Option under contingency of the certain events, as you said. Now: <<It's hard to imagine that Bristol "passed" if ENMD never tried to sell, since Bristol's rights are contingent apon that event.>> Do you believe that ENMD never tried to sell??? I am sick of this BS, so please let leave ENMD to ENMD tread. This tread is about CELG. Miljenko